Prof. Brigida Anna Maiorano, IRCCS San Raffaele Scientific Institute, Italy For patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, could the combination of enfortumab vedotin (EV) and pembrolizumab represent a transformative therapeutic advance? Prof. Maiorano examines the clinical potential of this regimen and discusses how cross-trial comparisons can help answer key questions that a single clinical trial cannot fully resolve.